
Supplements and Featured Publications
- My Treatment Approach: Chronic Lymphocytic Leukemia
- Volume 1
- Issue 1
Dr. Lunning on Initial Treatment Considerations in CLL
Matthew A. Lunning, DO, discusses initial treatment considerations in chronic lymphocytic leukemia.
Matthew A. Lunning, DO, assistant professor, Internal Medicine Division of Oncology & Hematology, University of Nebraska Medical Center, discusses initial treatment considerations in chronic lymphocytic leukemia (CLL).
Patients with CLL often present with asymptomatic disease that is identified with a routine complete blood count, Lunning explains.
To confirm a CLL diagnosis, patients typically undergo flow cytometry on peripheral blood, says Lunning. Afterward, a lymphocyte count, hemoglobin count, and platelet count should be conducted.
Additionally, patients should have a physical exam to identify splenomegaly, concerning adenopathy, or irregular lymph nodes, Lunning explains.
Richter’s transformation indicates a poorer prognosis and can significantly alter a patient’s treatment in the newly diagnosed or relapsed/refractory setting, concludes Lunning.
Articles in this issue
over 4 years ago
An Expert Provides Insight Into the Use of BTK Inhibitors in CLLabout 5 years ago
BTK Combos Seek to Raise the Bar in CLL Treatment Paradigmabout 5 years ago
BTK Inhibitor Combos Could Transform the Complex CLL Armamentariumabout 5 years ago
Dr. Awan on the Importance of Risk Stratification in CLLabout 5 years ago
Novel Agents Capture Attention in Newly Diagnosed CLL/SLLabout 5 years ago
Treatment Selection in CLL Broadens Beyond Discussions of Efficacyabout 5 years ago
Dr. Awan on the Importance of Collaborative Care in CLLover 5 years ago
Dr. Danilov on the Role of Chemoimmunotherapy in CLL


































